Tenax Therapeutics (TENX)
NASDAQ:TENX
Want to see TENX full AI Analyst Report?
TENX Stock Chart & Stats
$14.45
<$0.01(0.16%)
At close: 4:00 PM EST
$14.45
<$0.01(0.16%)
Day’s Range― - ―
52-Week Range$5.34 - $18.38
Previous CloseN/A
Volume25.45K
Average Volume (3M)510.83K
Market Cap
$259.86M
Enterprise Value$122.22M
Total Cash (Recent Filing)$97.56M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.45
Next Earnings
May 19, 2026EPS Estimate
-0.4Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.38
Shares Outstanding17,197,613
10 Day Avg. Volume577,990
30 Day Avg. Volume510,831
Financial Highlights & Ratios
PEG Ratio-0.55
Price to Book (P/B)4.92
Price to Sales (P/S)0.00
P/FCF Ratio-13.35
Enterprise Value/Market Cap0.47
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$31.50Price Target Upside117.99% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-1.56
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressCompletion of enrollment in the LEVEL Phase III study combined with a prespecified blinded sample size reassessment preserves statistical power and increases the chance of a decisive top-line efficacy result for levosimendan.
Commercial Opportunity And Unmet NeedA substantial unmet medical need and absence of approved therapies for pulmonary hypertension with preserved ejection fraction create a sizable market opportunity that could support strong adoption of an effective new treatment like levosimendan.
Differentiated Mechanism And HemodynamicsAnalyst highlights levosimendan's distinct mechanism and a larger reduction in pulmonary capillary wedge pressure versus a competing therapy, which could translate into meaningful clinical differentiation if confirmed in registrational trials.
Bears Say
Competitive LandscapeEncouraging data from larger rivals testing alternative agents could shift regulatory expectations and investor attention, increasing competitive pressure and making commercial success harder for smaller developers.
Diagnosis And Enrollment BarriersUnderdiagnosis of pulmonary hypertension with preserved ejection fraction and infrequent use of right-heart catheterization in some regions may limit identification of eligible patients, complicating trial recruitment and future market uptake.
Financial And Execution RiskA negative return on equity indicates ongoing unprofitable operations and heightens funding and execution risk, which could constrain the company's ability to advance development and commercial plans.
Tenax Therapeutics News
TENX FAQ
What was Tenax Therapeutics’s price range in the past 12 months?
Tenax Therapeutics lowest stock price was $5.33 and its highest was $18.38 in the past 12 months.
What is Tenax Therapeutics’s market cap?
Tenax Therapeutics’s market cap is $259.86M.
When is Tenax Therapeutics’s upcoming earnings report date?
Tenax Therapeutics’s upcoming earnings report date is May 19, 2026 which is in 19 days.
How were Tenax Therapeutics’s earnings last quarter?
Tenax Therapeutics released its earnings results on Mar 10, 2026. The company reported -$0.38 earnings per share for the quarter, beating the consensus estimate of -$0.414 by $0.034.
Is Tenax Therapeutics overvalued?
According to Wall Street analysts Tenax Therapeutics’s price is currently Undervalued.
Does Tenax Therapeutics pay dividends?
Tenax Therapeutics does not currently pay dividends.
What is Tenax Therapeutics’s EPS estimate?
Tenax Therapeutics’s EPS estimate is -0.4.
How many shares outstanding does Tenax Therapeutics have?
Tenax Therapeutics has 17,197,613 shares outstanding.
What happened to Tenax Therapeutics’s price movement after its last earnings report?
Tenax Therapeutics reported an EPS of -$0.38 in its last earnings report, beating expectations of -$0.414. Following the earnings report the stock price went up 31.67%.
Which hedge fund is a major shareholder of Tenax Therapeutics?
Currently, no hedge funds are holding shares in TENX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tenax Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$31.50 (117.99% Upside)
$31.50 (117.99% Upside)
Blogger Sentiment
Neutral
TENX Sentiment 50%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 494.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 2.7%
Last 30 Days ▲ 8.0%
Last 30 Days ▲ 8.0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
171.61%
12-Months-Change
Fundamentals
Return on Equity
-51.83%
Trailing 12-Months
Asset Growth
7.80%
Trailing 12-Months
Company Description
Tenax Therapeutics
Tenax Therapeutics, Inc., a specialty pharmaceutical company, engages in identifying, developing, and commercializing products for cardiovascular and pulmonary diseases in the United States and Canada. It develops TNX-103 and TNX-102 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of pulmonary arterial hypertension. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Morrisville, North Carolina.
TENX Stock 12 Month Forecast
Average Price Target
$31.50
▲(117.99% Upside)
Technical Analysis
Tempest Therapeutics
―
Relmada Therapeutics
―
VYNE Therapeutics
―
Longeveron
―
Calidi Biotherapeutics
―
Ownership Overview
0.19% Insiders
3.75% Mutual Funds
<0.01% Other Institutional Investors
94.14% Public Companies and
Individual Investors